| 发明名称 | Human cytomegalovirus neutralising antibodies and use thereof | ||
| 摘要 | The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease. | ||
| 申请公布号 | US9611316(B2) | 申请公布日期 | 2017.04.04 |
| 申请号 | US201514938438 | 申请日期 | 2015.11.11 |
| 申请人 | Institute for Research in Biomedicine | 发明人 | Lanzavecchia Antonio;Macagno Annalisa |
| 分类号 | A61K39/42;C07K14/005;A61K38/00;C07K16/08;C07K5/09 | 主分类号 | A61K39/42 |
| 代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;DiGiorgio, Esq. Jeanne M. |
| 主权项 | 1. A composition comprising an antibody, or an antigen binding fragment thereof, comprising the CDR1, CDR2, and CDR3sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs: 63 and 64, respectively, wherein the composition is in lyophilized form. | ||
| 地址 | Bellinzona CH | ||